Compound class
Multi-receptor incretin analogs
Single peptide molecules characterized against more than one receptor in the incretin and glucagon receptor families.
01
Neutral class definition
Single peptide molecules characterized against more than one receptor in the incretin and glucagon receptor families.
02
Related compounds
Compound
Mazdutide
Mazdutide is a lipidated synthetic peptide classified as a GLP-1 and glucagon receptor dual agonist, built on an oxyntomodulin-derived backbone.
IBI362 · IBI-362 · LY3305677 · LY-3305677 · IBI362 · LY3305677
Compound
Retatrutide
Retatrutide, development code LY3437943, is a single peptide characterized as an agonist at GCGR, GIPR, and GLP-1R in its discovery record.
LY3437943
Compound
Survodutide
Survodutide is a lipidated synthetic peptide agonist at both the GLP-1 receptor and the glucagon receptor, built on a modified glucagon-family backbone with a branched side-chain linker.
BI 456906 · BI-456906 · BI 456906
Compound
Tirzepatide
Tirzepatide is a fatty-acid-modified synthetic peptide characterized in its discovery record as having agonist activity at both the GIP receptor and the GLP-1 receptor.
LY3298176
03
Related molecular mechanisms
receptor
Glucagon-like peptide-1 receptor
GLP-1R is a class B G-protein-coupled receptor. The cited structural and pharmacology records characterize semaglutide and retatrutide as peptide agonists at this receptor.
receptor
Glucagon receptor
GCGR is a class B G-protein-coupled receptor. Retatrutide's LY3437943 discovery record characterizes a molecular agonist relationship at GCGR alongside GIPR and GLP-1R.
receptor
Glucose-dependent insulinotropic polypeptide receptor
GIPR is a class B G-protein-coupled receptor. The cited discovery and trial records identify it as one of the three receptor relationships declared for retatrutide.
04
Relevant glossary terms
05
Verified bibliography
Reference 1
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O'Farrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB, Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z
Cell metabolism · 2022-08-18 · Journal Article
currentReference 2
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML, Retatrutide Phase 2 Obesity Trial Investigators
The New England journal of medicine · 2023-06-26 · Clinical Trial, Phase II
currentReference 3
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T
Lancet (London, England) · 2023-06-26 · Clinical Trial, Phase II
current
Study models of these references
What kind of experiment each cited paper reports, taken from its abstract unless marked. Not a summary of results.
| Reference | Study models |
|---|---|
| Coskun T et al. 2022 | Study models reported: in vitro; animal (mouse); human participants (interventional) · from the abstract |
| Jastreboff AM et al. 2023 | Study models reported: human participants (interventional) · from the abstract |
| Rosenstock J et al. 2023 | Study models reported: human participants (interventional) · from the abstract |
06
Related Purely Peptides research articles
07